Outcome of Board Meeting held on Saturday, 30th May, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories Limited reported audited standalone revenue of Rs. 15,678.68 lakhs for FY 2025-26, with profit before tax of Rs. 1,086.56 lakhs. On a consolidated basis (including subsidiary Sriven Pharmachem India Private Limited), revenue jumped to Rs. 24,934.88 lakhs with profit before tax of Rs. 1,773.03 lakhs. The consolidated Q4 revenue was Rs. 13,414.52 lakhs, significantly higher than standalone Q4 revenue of Rs. 4,098.32 lakhs, showing the subsidiary's substantial contribution. The company reappointed M/s VRPS & Co. as Internal Auditors for FY 2026-27. Total consolidated assets stood at Rs. 51,419.47 lakhs. The company operates in pharmaceutical ingredients (bulk drugs) segment.
The substantial gap between standalone and consolidated revenue indicates significant subsidiary operations. Strong asset growth and profitability suggest business expansion, though the share capital increase from Rs. 984.56 lakhs to Rs. 4,223.72 lakhs warrants attention regarding dilution or capital restructuring.